SANXING(SH:601567) Mei Ri Jing Ji Xin Wen·2025-07-21 23:14Group 1 - Weikang Pharmaceutical's application for the listing of Vitamin K1 drops has been accepted, but it will not impact the company's recent performance due to the uncertainty of the registration approval timeline and results [1] - Samsung Medical's wholly-owned subsidiary has signed an overseas contract worth approximately 341 million RMB, which represents 2.33% of the company's projected revenue for 2024, indicating a strategic move to expand in the Brazilian market [2] - Vili Zhibo plans to list on the Hong Kong Stock Exchange on July 25, with an IPO valuation between 5.958 billion HKD and 6.599 billion HKD, aiming to accelerate clinical development and optimize its technology platform [3] Group 2 - United Pharmaceutical plans to raise over 2.2 billion HKD through a placement of new shares, with proceeds allocated for production facility expansion, external collaborations, and R&D of innovative candidates, highlighting the industry's financing vitality [4] - Jichuan Pharmaceutical's cooperative product, Marcilosavir tablets, has received a drug registration certificate, positioning it as a competitive broad-spectrum antiviral treatment for influenza, which may enhance the company's presence in the anti-infection sector [5]